Cytogen, DuPont Merck End Quadramet Agreement.(pain killer)(Brief Article)

Chemical Week, June, 1998 by Westervelt, Robert

Biopharmaceutical maker Cytogen says it has ended a licensing agreement with DuPont Merck for Quadramet, a pain relief drug for bone cancer patients. The companies recently settled a lawsuit brought by Cytogen after DuPont Merck said it would stop marketing the drug (CW, June 5, p. 14).

Under the agreement, DuPont Merck was responsible for manufacturing and marketing Quadramet in the U.S., while Cytogen was responsible for certain regulatory approvals and clinical development of Quadramet for other indications. To date, royalty payments to Cytogen have exceeded total sales of the medication.

DuPont Merck has begun efforts to identify and select a new partner to market the medication. DuPont Merck is expected to continue manufacturing Quadramet for the next...

Read the rest of this article with a Free Trial at HighBeam Research.

Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works.